|
|
|
|
|
|
|
Mon T W Th F |
|
29 June, 2026 |
|
|
|
|
|
|
|
|
|
|
|
|
A decade ago, companies relocating out of the US for tax purposes caught the eye of Washington. Today, it’s US companies forming deals with Chinese biotechs that are raising alarm bells in DC. Drew Armstrong writes about whether that parallel will stand. |
|
|
|
Karen Weintraub |
Deputy Editor, Endpoints News
|
|
|
|
|
|
|
by Drew Armstrong
|
About a decade ago, when I had just started covering pharma, one of the biggest stories was tax inversions. For those who don’t remember, tax... | |
|
|
|
 |
|
Kenneth Galbraith, Zymeworks CEO |
|
|
|
by Elizabeth Cairns
|
On the face of it, nearly $1 billion seems like a lot to spend on a biotech like Theravance. The company was clearly running out... | |
|
|
|
|
|
|
by Max Gelman
|
Evommune's shares EVMN fell more than 30% on Monday morning after the biotech reported its first major trial readout since going public last year. In... | |
|
|
|
|
|
|
|
|
by Lei Lei Wu
|
BioCryst Pharmaceuticals is winding down its own drug discovery work, saying that it plans to look for future drug programs externally. The company announceda... | |
|
|
|
|
|
